APEX1 and acute myeloid leukemia: The cytotoxic efficacy of talazoparib and APE1 inhibitor III was analyzed after 3 d of initial expansion followed by 3 d of treatment in CD34+ MDS/CMML cells (n = 8; 4 MDS and 4 CMML samples) and in CD34+ or CD34− AML cells (n = 18) in comparison to healthy CD34+ donor cells (n = 8) (Table 1, Figure 1).